Fact Source: Financial Supervisory Service DART / 2025-11-13
Disclosure Type: Supply Contract / Single Sales Contract (Amendment)
💡 3-Second Summary
Samsung Biologics has extended its non-disclosure confidentiality period regarding a 2019 contract manufacturing organization (CMO) agreement from the end of 2025 to March 8, 2033, following the client’s formal request.
📊 1. [Summary of Key Disclosure Content and Major Figures]
- Contract Name: Contract Manufacturing Agreement
- Contract Amount: KRW 48,948,354,540 (Based on the total contract value of USD 42,244,200 converted at the initial exchange rate of KRW 1,158.70/USD on the original disclosure baseline date of April 26, 2019)
- Ratio to Recent Sales: 9.14% (Compared to the 2018 consolidated financial statement revenue of KRW 535,805,801,067)
- Counterparty: A pharmaceutical company located in Asia (Kept confidential due to business secrets)
- Contract Period: April 26, 2019 ~ March 8, 2033 (End Date: 2033-03-08)
- Amendment Item (Disclosure Postponement Period): Before: 2025-12-31 → After: 2033-03-08
- Reason for Amendment: Extension of non-disclosure period at the client’s request
- Other Terms: No down payment or advance payment is included. The final contract end date and total amount may be altered upon mutual agreement. The identity of the counterparty is scheduled to remain sealed until after March 8, 2033.
📈 2. [Expert Insight: What This Disclosure Means for Investors]
This filing serves as an administrative amendment to a long-term manufacturing contract originally disclosed on April 26, 2019, adjusting only the timeline parameters rather than adding new orders or increasing contract value. Consequently, it does not bring any immediate fundamental changes to the company’s cumulative sales or current order backlog metrics.
The primary point for market participants to evaluate is the prolonged postponement of the non-disclosure deadline. The market previously expected the Asian client’s identity to become public after December 31, 2025. This amendment, however, pushes that visibility horizon back by more than seven years to coincide with the contract expiration date of March 8, 2033. While the explicit cause is noted as a “client’s request,” implying a steady operational partnership, it means investors face an extended duration of limited transparency regarding this asset. This specific filing does not explain the concrete causes behind any separate earnings fluctuations.
In conclusion, this disclosure represents an administrative duration adjustment rather than a market-moving event. Because the final contract duration and values could still vary upon subsequent mutual agreements, market participants should continue to assess this setup based on long-term supply continuity rather than short-term price adjustments.
📝 Editor’s Comment (by K-STOCK Editor)
For investors who had been waiting for the end of this year to finally find out which major Asian pharmaceutical firm partnered with Samsung Biologics back in 2019, this amendment brings a prolonged delay. The non-disclosure period has now been heavily pushed back until 2033. Within the global biopharmaceutical CMO sector, extending confidentiality terms to safeguard a client’s broader commercial roll-out timeline is a routine procedure, so immediate panic is unwarranted. Nevertheless, long-term shareholders must tolerate an extended window of data opacity, relying solely on baseline disclosure metrics. Since this filing centers purely on a duration extension without altering the contract value, avoiding over-interpretation and tracking the long-term partnership stability remains the most sensible approach.
📢 Disclaimer and Source Information
Source: This content has been newly structured and written based on the official data submitted to the Financial Supervisory Service’s DART system.
Investment Risk Notice: This information is provided solely for informational and linguistic reference purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any specific stock. All investment decisions and financial liabilities rest entirely with the investor.
Contact: For compliance inquiries or copyright-related requests, please contact ksb220805@gmail.com.
🔥 Bulls vs Bears, drop your analysis in the comments!
